The role of circulating miRNAs in multiple myeloma

Ji, Zhang; Xiao, Xiaojuan; Liu, Jing

doi:10.1007/s11427-015-4969-2

Cited by 25 publications

(20 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the era of new and most effective therapies for MM, the proteasome inhibitor BTZ and the immunomodulatory drugs thalidomide and lenalidomide, in particular, have rapidly improved MM therapy and patient outcomes [44]. However, the current clinical issues are drug resistance and relapse because of the heterogeneous genetic/epigenetic basis of the disease as well as noncoding regulatory RNA such as microRNA (miRNAs) and the bone marrow microenvironment components [45][46][47]. Ongoing studies aim to develop personalized therapies, immune-based therapies, next-generation targeted agents, and rationally based combinations of targeted therapies [4,47].…”

Section: Discussionmentioning

confidence: 99%

Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma

Roy

Liang

Xiao

et al. 2016

Blood

Self Cite

View full text Add to dashboard Cite

Multiple myeloma (MM) is largely incurable and drug-resistant. Novel therapeutic approaches such as inhibiting autophagy or rational drug combinations are aimed to overcome this issue. In this study, we found that lycorine exhibits a promising anti-proliferative activity against MM in vitro and in vivo by inhibiting autophagy. We identified High mobility group box 1 (HMGB1), an important regulator of autophagy, as the most aberrantly expressed protein after lycorine treatment and as a critical mediator of lycorine activity. Gene expression profiling (GEP) analysis showed that higher expression of HMGB1 is linked with the poor prognosis of MM. This correlation was further confirmed in human bone marrow CD138 + primary myeloma cells and MM cell lines. Mechanistically, proteasomal degradation of HMGB1 by lycorine inhibits the activation of MEK-ERK thereby decreases phosphorylation of Bcl-2 resulting in constitutive association of Bcl-2 with Beclin-1. In addition, we observed higher HMGB1 expression in bortezomib resistant cells and the combination of bortezomib plus lycorine was highly efficient in vitro and in vivo myeloma models as well as in re-sensitizing resistant cells to bortezomib. These observations indicate lycorine as an effective autophagy inhibitor and reveal that lycorine alone or in combination with bortezomib is a potential therapeutic strategy.

show abstract

Section: Discussionmentioning

confidence: 99%

Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma

Roy

Liang

Xiao

et al. 2016

Blood

Self Cite

View full text Add to dashboard Cite

show abstract

“…Dysregulated circulatory miRNAs have been served as biomarkers for diagnosis, prognosis and prediction in hematopoietic neoplasias [11]. In recent years, several studies have reported that circulating miRNAs were involved in pathogenesis and therapy prediction in CML patients.…”

Section: Research Papermentioning

confidence: 99%

“…However, it is less frequently used due to the increased starting material requirements and costly expense. In contrast, microarray can be performed with less amount of material [11,23]. As miRNA abundance in plasma is very low, and the total amount of miRNA extracted by using miReasy Serum/Plasma kit is very little, microarray is still widely used in the detection of plasma miRNA [24][25][26].…”

Section: Oncotarget S474 Wwwimpactjournalscom/oncotargetmentioning

confidence: 99%

WITHDRAWN: Expression profiles and biological implications of plasma miRNAs associated with chronic myeloid leukemia phases

Zhang¹,

Jiang²,

Han³

et al. 2018

Oncotarget

Self Cite

View full text Add to dashboard Cite

ABSTRACTmicroRNAs play important regulatory roles in hematologic malignancies, and dysregulation of circulating miRNAs serves as diagnostic, prognostic and predictive biomarkers in many diseases. The correlation of plasma miRNA profiles with the progression of chronic myeloid leukemia (CML) has not been investigated. We have applied microarrays to identify differentially expressed miRNAs, followed by qRT-PCR to validate candidate miRNAs from four sample pools including chronic phase (CP), accelerated phase(AP), blast crisis(BC) and healthy control. Clustering analyses revealed varying phase-specific patterns of plasma miRNA expression during CML progression. Different phases of CML showed differential expression profiles between sample pools during the progression. The functional annotation tool, DAVID, found that putative targets of dysregulated miRNAs in different phases of diease are involved in several important signaling pathways. Gradually decreased expression levels of miR-451a were validated in CML patients from the CP to AP and BC; when CML patients achieved major molecular response (MMR), miR-451a expression was increased and restored to normal range. These data provide an important resource for studies on CML progression and allow a better understanding of the fundamental differences in plasma miRNA expression profiles among the different phases of CML.

show abstract

“…GCTBs are also characterized by extensive bone resorption, which results in regional pain and bone destruction, mostly occurring in distal femur, proximal tibia, distal radius, and sacrum [32,33]. Histologically, GCTBs can be classified into three main types, which are osteoclast-like multinucleated giant cells, monocytic round cells, and spindle-like stromal cells [34]. Current treatments of GCTBs are ranging from intralesional curettage to wide resection [33].…”

Section: Benign Bone Tumor: Giant Cell Tumormentioning

confidence: 99%

MicroRNAs in Bone Diseases: Progress and Prospects

Loh¹,

Lau²,

Lai³

et al. 2018

Transcriptional and Post-Transcriptional Regulation

View full text Add to dashboard Cite

With 19-25 nucleotides long, microRNAs (miRNAs) are small noncoding RNA molecules which play crucial roles in major cellular functions such as cell cycle control, apoptosis, metabolism, cell proliferation, and cell differentiation. Changes in the expression of miRNAs can cause significant effects to normal and aberrant cells. The dysregulation of miRNAs has been implicated in various human diseases such as brain tumor, osteoarthritis, schizophrenia, and breast cancer. Generally, miRNAs negatively regulate gene expression by binding to their specific mRNAs, thereby blocking their translation of the mRNAs. However, a few studies have reported that miRNAs could also upregulate the translation of certain proteins. This shows the important roles of miRNAs in various cell functions. This chapter will focus on the role of miRNAs in normal osteoblast and osteosarcoma cells. In addition, the great potential of miRNA as a new therapeutic approach to treat human bone diseases will also be discussed.

show abstract

The role of circulating miRNAs in multiple myeloma

Cited by 25 publications

References 58 publications

Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma

Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma

WITHDRAWN: Expression profiles and biological implications of plasma miRNAs associated with chronic myeloid leukemia phases

MicroRNAs in Bone Diseases: Progress and Prospects

Contact Info

Product

Resources

About